HCA Healthcare, the largest for-profit hospital chain in the United States, posted Q2 2026 revenue of $20.230 billion (+8.7% year over year), net income attributable to the company of $1.699 billion (+2.8%, diluted EPS $7.62), and adjusted EBITDA of $4.027 billion (+4.6%) (per the company's earnings press release). Behind the headline growth, two opposing forces are in direct conflict: the one-time revenue recognition tied to Florida's Directed Payments Program (DPP) and the 23.3% surge in uninsured admissions triggered by the expiration of the Enhanced Premium Tax Credit (EPTC). Operating cash flow on a standalone Q2 basis collapsed 44.5%, from $4.210 billion to $2.335 billion (the six-month cumulative figure fell 25.8%, from $5.861 billion to $4.349 billion), and accounts receivable swelled by $1.414 billion over six months, raising collection risk.
Most notably, the company lowered its 2026 full-year guidance alongside the results — net income from $6.495–7.035 billion to $6.300–6.700 billion, adjusted EBITDA from $15.55–16.45 billion to $15.40–16.10 billion, and diluted EPS from $29.10–31.50 to $28.70–30.50. The real story this quarter lies not in the income statement but in the cash flow statement, the balance sheet, and a forecast that management itself has marked down.
1. Consolidated Balance Sheet Analysis
1-1. Key Asset Line Items (Dec 31, 2025 → Jun 30, 2026)
| Item | Prior Period ($ millions) | Current Period ($ millions) | Change | Interpretation |
|---|---|---|---|---|
| Cash and cash equivalents | 1,040 | 1,013 | -2.6% | Defended by new bond issuance despite $3.6B in share repurchases |
| Accounts receivable | 10,867 | 12,281 | +13.0% | Uncollected Florida DPP and Medicaid supplemental payment accruals — direct cause of operating cash decline |
| Inventories | 1,652 | 1,662 | +0.6% | Essentially flat — no material interpretation warranted |
| Property, plant & equipment (net) | 31,141 | 31,816 | +2.2% | 6M capex of $2.350B (vs. $2.167B prior year, +8.4%) — ongoing growth and facility investment |
| Goodwill and intangible assets | 10,293 | 10,662 | +3.6% | Reflects $386M acquisition of non-hospital healthcare assets |
Key takeaway: The 13.0% rise in accounts receivable (+$1.414 billion) reflects retroactive Florida DPP revenue of $1.372 billion (of which approximately $980 million relates to pre-2026 periods) that has been recognized as revenue but not yet collected in cash. Medicaid revenue for the quarter accordingly surged from $1.440 billion to $2.789 billion, +93.7%. In other words, a substantial portion of this quarter's revenue growth stems from one-time catch-up recognition tied to CMS (Centers for Medicare & Medicaid Services) approval timing, and this contribution will diminish in subsequent quarters. (All figures per the Form 10-Q text and notes.)
1-2. Debt Structure — Financial Liability-Led Increase
Total financial debt (gross borrowings): $46.492 billion → $49.718 billion (+6.9%, +$3.226 billion) - Commercial paper (CP): $2.207 billion → $3.890 billion (+76.3%) — average maturity 38 days, weighted-average rate 4.3% - Unsecured revolving credit facility: $0 → $1.010 billion drawn (effective rate 4.8%) — the single most notable item in this quarter's debt increase - Unsecured senior notes: $43.700 billion → $44.200 billion (April: $3.0B in new notes due 2031, 2033, and 2036; May: $2.5B in 2026 maturities repaid) - Other borrowings: $1.021 billion → $1.069 billion - Long-term debt average maturity: 11.7 years; average rate: 5.1%
Operating liabilities: accounts payable $4.752B (+2.0%), accrued wages $2.199B (-12.9% — reflecting bonus payments), other accrued expenses $4.097B (-4.2%) — all stable. Debt growth was driven almost entirely by financial liabilities, with the notable rise in short-term CP and the inaugural revolver draw standing out.
At June 30, the fair value of the debt was $48.640 billion, $1.529 billion below the carrying amount of $50.169 billion before netting issuance costs and discounts (the balance sheet total of $49.718 billion nets those items out). The discount widened from $1.017 billion at year-end, reflecting market rates and credit spreads — this does not reduce the principal HCA must repay.
1-3. Capital Structure — Deepening Stockholders' Equity Deficit
- Common stock: $0.01 par × 218 million shares = $2 million (nominal)
- Retained earnings (deficit): -$5.724 billion → -$6.310 billion (deficit widened by $586 million)
- Noncontrolling interests: $3.256 billion → $3.433 billion
- Total equity: -$2.771 billion → -$3.209 billion
HCA operates in a structural stockholders' equity deficit. Despite generating $3.787 billion in net income over six months, share repurchases of $3.635 billion, dividends of $354 million, and noncontrolling interest distributions of $334 million collectively exceeded earnings. This is not a sign of deteriorating financial health but rather an intentional leveraged capital allocation strategy — typical of LBO-pedigreed public companies that borrow to repurchase shares and amplify EPS, backed by stable cash generation.
2. Consolidated Income Statement Analysis
2-1. Key Earnings Metrics (Q2 2026 vs. Q2 2025)
| Item | Prior Period ($ millions) | Current Period ($ millions) | Change |
|---|---|---|---|
| Revenue | 18,605 | 20,230 | +8.7% |
| Operating income (before interest & taxes) | 2,986 | 3,083 | +3.2% |
| Operating margin | 16.0% | 15.2% | -0.8 pp |
| Adjusted EBITDA (company-reported) | 3,849 | 4,027 | +4.6% |
| Net income attributable to HCA Healthcare | 1,653 | 1,699 | +2.8% |
| Net margin | 8.9% | 8.4% | -0.5 pp |
| Diluted EPS | $6.83 | $7.62 | +11.6% |
Volume vs. price: equivalent admissions +2.6%, revenue per equivalent admission +6.0%. However, inpatient surgeries fell 2.3% and outpatient surgeries fell 4.4%, indicating higher-margin elective procedure volumes are declining. Growth in emergency room visits (+3.5%) and uninsured admissions (+23.3%) signals that patients losing exchange coverage due to EPTC expiration are redirecting to emergency departments.
The extent to which Florida DPP drove revenue growth is quantifiable. Of the $1.625 billion revenue increase in the quarter, DPP-related incremental revenue accounted for $1.372 billion; stripping out the prior-period retroactive portion of approximately $980 million reduces the underlying revenue growth rate from +8.7% to approximately +3.5%. That is the actual scale of core operational momentum this quarter.
2-2. Cost Structure (Six-Month Cumulative, Consolidated)
- Salaries & benefits: $16.573 billion (vs. $16.135 billion, +2.7%), declining as a share of revenue to 42.1% (from 43.7%), a 1.6-pp improvement
- Supplies: $5.739 billion (vs. $5.608 billion, +2.3%), 14.6% of revenue (from 15.2%)
- Other operating expenses: $9.223 billion (vs. $7.638 billion, +20.8%), rising as a share of revenue to 23.5% from 20.7% (+2.8 pp)
- Depreciation & amortization: $1.874 billion (+8.8%) / Interest expense: $1.183 billion (+6.1%)
- Corporate office costs: $281 million (vs. $256 million, +9.8%). The "Corporate and Other" segment EBITDA adjustment line was $662 million (vs. $631 million, +4.9%)
Note: The segment table salary totals — National $3.931B + Atlantic $4.579B + American $4.564B = $13.074B — differ from the consolidated $16.573 billion because they exclude corporate and other unallocated items. These segment figures should not be used to derive the 42.1% revenue ratio.
Operating leverage diagnosis: Six-month revenue rose 6.5% ($36.926B → $39.339B), while salaries grew only 2.7% and supplies only 2.3%, improving both line items as a share of revenue. However, other operating expenses surged 20.8% — driven by Florida DPP-related costs (a $557 million six-month retroactive amount) and higher professional fees — pushing that ratio up 2.8 pp, the primary cause of the operating margin contraction (16.0% → 15.2%). Rising D&A (+8.8%, from new facility openings) also outpaced revenue growth, adding incremental margin pressure.
The 6.1% rise in interest expense was not caused by higher rates on new debt, as is commonly assumed. The 10-Q shows the average effective rate actually fell from 5.1% to 4.9%, while the average outstanding balance expanded from $44.061 billion to $48.256 billion. Volume of debt, not its cost, drove interest expense higher.
The burden of uncompensated care also intensified. On a six-month basis, charity care costs totaled $1.018 billion, up 36.6% from $745 million in the prior year. EPTC expiration is routing uninsured patients to hospitals, and the cost of that care flows directly to the expense line.
3. Cash Flow Statement Analysis (Six-Month Cumulative)
| Item | Prior Period ($ millions) | Current Period ($ millions) | Change |
|---|---|---|---|
| Operating cash flow | 5,861 | 4,349 | -1,512 (-25.8%) |
| Investing cash flow | -2,283 | -2,839 | -556 (deteriorated) |
| Financing cash flow | -4,584 | -1,534 | +3,050 |
| Ending cash | 939 | 1,013 | +74 |
Period note: The -44.5% figure in the headline and lead is Q2 standalone ($4.210B → $2.335B); the -25.8% in the table above is the six-month cumulative figure. Both are stated in the 10-Q and are not contradictory — the decline was concentrated in Q2.
The source of the operating cash decline: Net income rose 1.9% to $3.787 billion (controlling interest: $3.319 billion, +1.7% YoY). The company attributes the $1.512 billion six-month decline to working capital deterioration of $1.099 billion (primarily a $1.417 billion increase in accounts receivable from Medicaid directed payments and supplemental payment programs) and a $579 million increase in income tax payments. The latter reflects a base effect: the IRS granted Tennessee-based taxpayers a deferral of quarterly estimated tax payments through Q4 2025. On a standalone Q2 basis, the causes were working capital deterioration of $1.413 billion and a $594 million increase in income tax payments. Combined interest and tax cash outflows for the six-month period totaled $1.888 billion (vs. $1.220 billion prior year). Accounting earnings are intact; the speed at which they convert to cash has slowed.
Investing activities: Capex of $2.350 billion (vs. $2.167 billion, +8.4%) for ongoing facility expansion; $386 million for non-hospital healthcare acquisitions; hospital divestiture proceeds of just $21 million — effectively a net-acquirer posture. The company guided full-year 2026 capex to $5.0–5.5 billion.
Financing activities: Share repurchases of $3.635 billion (vs. $5.011 billion), dividends of $354 million, net debt increase of $3.065 billion (issuances $2.994B + CP $2.679B – repayments $2.608B) — net borrowing expanded to fund capital returns. Share repurchases consumed 84% of six-month operating cash flow, an aggressive return posture.
Free cash flow (FCF) = $4.349B – $2.350B = $1.999 billion (vs. $3.694 billion prior year, -45.9%). FCF halved — the most damaging number in this quarter's report. It signals narrowing room for share repurchases and, if receivables recovery stalls through Q3 and Q4, potential further growth in CP and revolver balances. For reference, working capital at June 30 was -$122 million (vs. -$567 million at year-end); excluding CP, it was +$3.768 billion.
4. Six Issues That Demand Attention
① 2026 guidance cut — the actual headline of this release: The company lowered full-year guidance to net income $6.300–6.700 billion (from $6.495–7.035B), adjusted EBITDA $15.40–16.10 billion (from $15.55–16.45B), and diluted EPS $28.70–30.50 (from $29.10–31.50). Revenue guidance was narrowed to $77.0–79.5 billion (from $76.5–80.0B). The estimated annual headwind from exchange-market changes widened from ($600–900 million) to ($1.000–1.200 billion), while the expected Medicaid supplemental payment program benefit increased from ($50–250 million) to +$300–500 million. Management is in effect conceding that Medicaid gains are insufficient to fully offset the EPTC-driven hole.
② Florida DPP approval — a double-edged recognition: Q2 incremental revenue of $1.372 billion, associated other operating costs of $829 million (retroactive for Oct 2024–Jun 2026). The simple spread is $543 million, but the company-disclosed net Q2 Medicaid supplemental payment program benefit is approximately $400 million. The critical point is that this is a one-time retroactive catch-up — from Q3 onward, only the regular quarterly recognition amount remains. The Atlantic Group's Q2 EBITDA jumped from $1.352 billion to $1.827 billion (+35.1%) largely because of this item. A sharp reversal in Atlantic Group results in Q3 is a material risk.
③ EPTC expiration — a structural headwind that precisely offsets the DPP gain: The expiration of enhanced premium tax credits at end-2025 caused a large cohort of exchange enrollees to lose coverage. Q2 uninsured admissions rose 23.3%; total uncompensated care costs for Q2 reached $1.445 billion, up 29.5% from $1.116 billion (charity care costs alone: $511M vs. $395M, +29.4%). Managed care and insurance revenue fell from $9.124 billion to $9.013 billion and its share of total revenue dropped 4.5 pp to 44.6%. The company disclosed that this payer mix deterioration produced an approximately $400 million pretax income headwind in Q2 — nearly exactly offsetting the ② Medicaid net benefit of $400 million. This structural pressure is expected to persist for four to six quarters.
④ $7.21 billion in remaining share repurchase authorization: The board authorized $10 billion programs in January 2025 and January 2026; the 2025 authorization was exhausted by Q1 2026. The 2026 program had $7.210 billion remaining at June 30. In H1, the company repurchased 7.909 million shares at an average of $447.53 per share. Whether management maintains or slows the repurchase pace given FCF compression will largely determine the direction of H2 EPS. Issued shares outstanding at June 30 were 218 million.
⑤ Segment divergence: American Group Q2 EBITDA fell from $1.578 billion to $1.369 billion (-13.2%); National Group from $1.271 billion to $1.184 billion (-6.8%). Strip out the one-time Atlantic Group windfall, and core operating regions are under margin pressure. Texas and Florida — home to 103 hospitals — accounted for 55% of Q2 revenue and 73% of uninsured admissions, a concentration that amplifies both the DPP upside and the EPTC downside.
⑥ Concentrated regulatory risk: The 2025 Federal Budget Act (FBA), CMS Medicaid reform, tariff policy, and sequestration spending cuts all appear in the 10-Q outlook section — an unusually dense list of policy variables. For a for-profit hospital operator, a single policy change can move quarterly EBITDA by hundreds of millions of dollars.
5. Key Takeaways and Outlook
Bull case: Emergency department demand and equivalent admissions (+2.6%) remain solid, and Florida program recognition continues in H2 at its recurring quarterly rate. The diluted share count fell 7.9% — from 241.911 million to 222.828 million — through repurchases, which is why EPS grew +11.6% even though net income rose only 2.8% (year-end shares outstanding: 218 million). The fact that most EPS growth came from share-count reduction rather than earnings growth is a double-edged dynamic. Newly issued notes priced at 4.7–5.3%, and the average effective rate on total debt fell to 4.9%, keeping financing costs manageable.
Bear case: EPTC expiration headwinds are still building — the company widened its exchange-impact estimate to ($1.0–1.2 billion) annually, signaling further deterioration in Q3 and Q4. If receivables collection stalls, CP and revolver balances will climb further, increasing interest expense. Sustained FCF compression of 45.9% would likely force a reduction in the 2027 share repurchase program. A $3.2 billion equity deficit leaves limited cushion if credit spreads widen and refinancing costs rise.
Bottom line: This quarter is best described as an accounting income win, a cash flow retreat, and a management-marked-down forecast. Before being drawn in by the headline growth rates — revenue +8.7%, EPS +11.6% — three figures demand scrutiny: ① underlying revenue growth excluding retroactive items, approximately +3.5%; ② FCF -45.9%; and ③ lowered full-year diluted EPS guidance of $28.70–30.50. The Q3 earnings release — which will quantify the magnitude of the Atlantic Group's reversal from its Q2 DPP windfall — represents a natural inflection point for reassessing the stock's trajectory.
This report is prepared for informational purposes based on HCA Healthcare's Form 10-Q for Q2 2026 (period ending June 30, 2026) filed with the SEC and the company's Q2 2026 earnings press release. It does not constitute investment advice.
